ArticleJournal of the American Heart Association2025
Surgical, Hybrid, or Delayed Surgical Stage 1: Single-Ventricle Palliation Pathway Utilization and Outcome Trends.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathways for single-ventricle palliation include traditional neonatal surgical stage 1 palliation (SP), hybrid stage 1 palliation (HP; pulmonary artery flow restriction with ductal stenting), and delayed surgical stage 1 palliation (DSP), preceded by pulmonary artery flow restriction and prostaglandins. Findings from studies aiming to determine the optimal pathway are conflicting. We aimed to describe current pathway utilization and outcomes.
methodsUsing the Pediatric Health Information System between January 2016 and August 2023, we identified 1872 patients who underwent single-ventricle palliation (1573 SP, 123 DSP, and 176 HP).
resultsPrematurity or low birth weight (<2.5 kg) were most common for DSP (52.9%) compared with SP (15.3%) and HP (36.4%) (
conclusionsDSP was used for patients with a higher rate of prematurity, lower birth weight, and more noncardiac comorbid conditions. HP, however, was associated with higher in-hospital mortality and index hospitalization transplant. Further study to determine the potential benefit of DSP for high-risk patients is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.